CIBC World Markets Inc. trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN) by 32.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,772 shares of the company’s stock after selling 25,300 shares during the quarter. CIBC World Markets Inc.’s holdings in AstraZeneca were worth $2,674,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. OLD Mission Capital LLC acquired a new stake in shares of AstraZeneca in the third quarter valued at approximately $7,581,000. Victory Capital Management Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $2,884,000. First Trust Advisors LP purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $54,011,000. Focused Wealth Management Inc raised its stake in shares of AstraZeneca by 16.8% during the fourth quarter. Focused Wealth Management Inc now owns 1,392 shares of the company’s stock worth $70,000 after purchasing an additional 200 shares during the last quarter. Finally, CIBC Asset Management Inc raised its stake in shares of AstraZeneca by 59.3% during the fourth quarter. CIBC Asset Management Inc now owns 52,763 shares of the company’s stock worth $2,638,000 after purchasing an additional 19,644 shares during the last quarter. 16.13% of the stock is owned by hedge funds and other institutional investors.
AZN has been the subject of several analyst reports. Argus restated a “hold” rating on shares of AstraZeneca in a research note on Monday, April 19th. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 25th. Jefferies Financial Group upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Tuesday, March 16th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research report on Monday, March 8th. Finally, Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. AstraZeneca has an average rating of “Buy” and a consensus price target of $99.33.
AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, April 29th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.11. AstraZeneca had a return on equity of 41.94% and a net margin of 14.42%. The business had revenue of $7.32 billion during the quarter, compared to analysts’ expectations of $7.15 billion. During the same quarter last year, the business posted $1.05 earnings per share. The business’s revenue for the quarter was up 15.2% on a year-over-year basis. Analysts forecast that AstraZeneca PLC will post 2.47 EPS for the current year.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Featured Story: How a Back-End Load Mutual Fund Works
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.